Gapping up
In reaction to strong earnings/guidance:
- HEI +2.3% (also increased dividend), LLY +1.2% (raises FY20 guidance)
Other news:
- TGE +21% (announces agreement for the purchase of its publicly-held class a shares by Blackstone Infrastructure Partners (BIP) for $22.45/share)
- IMGN +15.7% (reports top-line data from new pivotal single-arm trial, SORAYA, expected in first half of 2021; confirmatory MIRASOL trial for Mirvetuximab on track to start by year-end)
- BHVN +7.7% (announces 'positive' results from Phase 2/3 clinical trial evaluating the efficacy and tolerability of intranasal vazegepant 5, 10 and 20 mg versus placebo in 1,673 patients for the acute treatment of migraine)
- PCG +5.3% (amends restructuring support agreement)
- AGIO +5.1% (receives Breakthrough Therapy Designation for TIBSOVA from the FDA)
- ALNY +4.9% (announces that the ILLUMINATE-A Phase 3 study of lumasiran for the treatment of primary hyperoxaluria type 1 met its primary efficacy endpoint)
- PRVL +4.7% (drug candidate granted orphan drug designation)
- TME +3.6% (announces $400 mln share repurchase program)
- PCRX +3.1% (announced positive results from its Phase 3 PLAY study of EXPAREL in pediatric patients undergoing spinal or cardiac surgeries)
- NEX +3% (announces appointment of Kenneth Pucheu as CFO, effective immediately)
- NOG +2.1% (to commence $0.015/share quarterly cash dividend payment in April 2020)
- LLY +1.2% {dividend increase)
- PFE +0.9% (announce FDA approval of XTANDI for the treatment of metastatic castration-sensitive prostate )
Analyst comments:
- OII +4.8% (upgraded to Buy from Neutral at Goldman)
- GES +4% (upgraded to Outperform from Market Perform at Cowen)
- PI +3.4% (upgraded to Buy from Hold at Needham)
- FCX +1.6% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- JNJ +1.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)